Sugi Predict

Sugi Predict / Compounds / SCHEMBL5052045

SCHEMBL5052045

SCHEMBL5052045

CCCCCCCCCCCCCCCCCC(=O)O[C@H](CO)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.82
▸ NR5A2 O00482 1/20 0.82
▸ NR5A1 Q13285 1/20 0.82
▸ RECQL P46063 1/20 0.76
▸ MAPT P10636 3/20 0.72
▸ ALDH1A1 P00352 2/20 0.66
▸ ADRA1D P25100 1/20 0.64
▸ PTAFR P25105 1/20 0.64
▸ HTR1D P28221 1/20 0.64
▸ HTR2C P28335 1/20 0.64
▸ ADRA1B P35368 1/20 0.64
▸ DRD3 P35462 1/20 0.64
▸ TMEM97 Q5BJF2 1/20 0.64
▸ FABP3 P05413 1/20 0.63
▸ MAPK1 P28482 5/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ GMNN O75496 2/20 0.61
▸ LMNA P02545 2/20 0.61
▸ BLM P54132 2/20 0.61
▸ KMT2A Q03164 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405099 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3408948 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3404098 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3404363 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3407192 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3409187 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL6287175 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL5058577 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL1270228 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3406792 1.00 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109596748-B Method for detecting metabolites of gandi capsules for treating diabetic nephropathy patients 上海交通大学医学院附属新华医院 2022-03-04 — — CN claimed
US-20080160313-A1 Lipid bilayers on nanotextured solid surfaces ENERGY, U.S. DEPARTMENT OF 2008-07-03 — — US claimed
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE SAGIMET BIOSCIENCES INC. 2025-05-22 — — US disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
EP-3338088-B1 BIOMARKERS FOR CORONARY HEART DISEASE BGI SHENZHEN (CN) 2025-01-08 — — EP disclosed
CN-118924841-A Application of polygonatum odoratum extract in preparation of medicine for improving type 2 diabetes 浙江树人学院 2024-11-12 — — CN disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed
EP-4037718-A1 LIPOSOMES COMPRISING ANTI-LOX ANTIBODY Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. (IT) 2022-08-10 — — EP disclosed
US-20220128556-A1 METHODS OF DIAGNOSING DISEASE 4D Pharma Cork Limited (IE) 2022-04-28 — — US disclosed
CN-109596748-B Method for detecting metabolites of gandi capsules for treating diabetic nephropathy patients 上海交通大学医学院附属新华医院 2022-03-04 — — CN disclosed
CN-109507337-B Novel method for predicting mechanism of Gandi capsule for treating diabetic nephropathy based on metabolites in hematuria 上海交通大学医学院附属新华医院 2022-02-22 — — CN disclosed
CN-114040986-A Method of diagnosing disease 4D制药科克有限公司 2022-02-11 — — CN disclosed
EP-3947743-A1 METHODS OF DIAGNOSING DISEASE 4D Pharma Cork Limited (IE) 2022-02-09 — — EP disclosed
EP-3120872-B1 DUAL-PURPOSE PAT/ULTRASOUND CONTRAST AGENT BOUND WITH NANOPARTICLES CONTAINING DRUG AND METHOD FOR PREPARING SAME IMGT CO LTD (KR) 2021-06-09 — — EP disclosed
US-10912848-B2 Dual-purpose PAT/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same IMGT CO, LTD. (KR) 2021-02-09 — — US disclosed
US-20170080114-A1 Dual-Purpose Pat/Ultrasound Contrast Agent Bound with Nanoparticles Containing Drug and Method for Preparing Same IMGT CO, LTD. (KR) 2017-03-23 — — US disclosed
EP-3120872-A1 DUAL-PURPOSE PAT/ULTRASOUND CONTRAST AGENT BOUND WITH NANOPARTICLES CONTAINING DRUG AND METHOD FOR PREPARING SAME IMGT Co, Ltd. (KR) 2017-01-25 — — EP disclosed
WO-2015141917-A1 DUAL-PURPOSE PAT/ULTRASOUND CONTRAST AGENT BOUND WITH NANOPARTICLES CONTAINING DRUG AND METHOD FOR PREPARING SAME 서강대학교 산학협력단 2015-09-24 — — WO disclosed
US-20080160313-A1 Lipid bilayers on nanotextured solid surfaces ENERGY, U.S. DEPARTMENT OF 2008-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE ACACB, ACACA, ACLY SMN1; SMN2 3806/4885NR5A2 2080/4885NR5A1 1779/4885
US-10912848-B2 Dual-purpose PAT/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same DUOX2, PLAT, NPPA SMN1; SMN2 4857/4885NR5A2 2032/4885NR5A1 3179/4885
US-20170080114-A1 Dual-Purpose Pat/Ultrasound Contrast Agent Bound with Nanoparticles Containing Drug and Method for Preparing Same DUOX2, PLAT, NPPA SMN1; SMN2 4857/4885NR5A2 2032/4885NR5A1 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.